logo
ReposiTrak Adds 30 Cheese Suppliers to the Queue, Including Domestic Producers and Importers

ReposiTrak Adds 30 Cheese Suppliers to the Queue, Including Domestic Producers and Importers

Business Wire22-07-2025
SALT LAKE CITY--(BUSINESS WIRE)--ReposiTrak (NYSE:TRAK), the world's largest food traceability and regulatory compliance network, leveraging its established inventory management and out-of-stock reduction SaaS platform, is proud to add 30 purveyors of domestic and imported cheese to the queue of companies joining the ReposiTrak Traceability Network® (RTN). These companies will efficiently exchange intricate, FDA-required Key Data Elements (KDEs) for each Critical Tracking Event (CTE) in their supply chains, with the goal of meeting the growing traceability demands of their retail customers.
'We help cheese suppliers to meet the many different traceability requirements of each of their customers,' said ReposiTrak Chairman and CEO Randy Fields.
Share
The suppliers who are preparing for traceability include a California-based importer and processor of Italian cheeses and olive oils, including many grated and shredded varieties; an organic, grass‑based dairy processor out of Delaware; and a Columbia-based company that works with local farmers producing fresh, authentic dairy products derived from 100% grass-fed buffalo milk.
'Many traceability programs require food traceability data for all foods – or entire categories of food such as cheese. That's because there is risk for the retailer if food traceability data is missing, incomplete or inaccurate,' said ReposiTrak Chairman and CEO Randy Fields. 'We help cheese suppliers to meet the many different traceability requirements of each of their customers.'
The ReposiTrak Traceability Network requires no additional hardware. Every traceability data file is checked using a 500+ point error detection process and ReposiTrak's U.S.-based team works with suppliers to make corrections, so that the data is as complete and accurate as possible before it reaches their retail, wholesale or foodservice customers.
About ReposiTrak
ReposiTrak (NYSE: TRAK) provides retailers, suppliers, food manufacturers and wholesalers with a robust solution suite to help reduce risk and remain in compliance with regulatory requirements, enhance operational controls and increase sales with unrivaled brand protection. Consisting of three product families – food traceability, compliance and risk management and supply chain solutions – ReposiTrak's integrated, cloud-based applications are supported by an unparalleled team of experts. For more information, please visit https://repositrak.com
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Figma's CEO Stands to Make Billions Post-IPO. Here's What's In His Pay Package
Figma's CEO Stands to Make Billions Post-IPO. Here's What's In His Pay Package

Yahoo

time25 minutes ago

  • Yahoo

Figma's CEO Stands to Make Billions Post-IPO. Here's What's In His Pay Package

Key Takeaways Figma CEO Dylan Field stands to be very wealthy if he can hit the marks outlined in his pay package. The design software maker's trading debut puts big awards within reach. Field could make $1.9 billion if Figma's stock price reaches the highest hurdle, or $130, within 10 years of its (FIG) is shooting the lights out on its trading debut. The latest big IPO stands to make co-founder and chief Dylan Field very rich. The design software maker's shares recently traded around $108, a few bucks below intraday highs. (Its IPO priced at $33 per share, above an upwardly revised range of $30 to $32.) That first-day action puts Field's performance-based executive compensation awards well within reach. Some 14.5 million shares in restricted stock units have been set aside as a stock price award, split across seven tranches, according to filings. If the shares' 60-day average price hits $60, the low end of targets, Field would unlock $130 million worth. If the stock meets the highest hurdle, or $130, that package would grow to $1.9 billion. Field has 10 years to hit those marks. That doesn't include the 22.5 million shares split between service- and market-based awards Figma granted Field in 2021, which can be unlocked sooner. There are 7.9 million shares of Class B common stock that Field can vest as part of his service-based package, which are worth roughly $670 million based on the the stock's $85 Thursday open. There is also a CEO market reward that grants Field an additional 11.25 million shares separated into three tranches tied to laddered market-valuation targets of $15 billion, $20 billion, and $25 billion. And there's cash: Figma's board in 2024 raised Field's base salary to $500,000 from $450,000. Field can thank Elon Musk and his richly-valued pay package at Tesla (TSLA) for raising the compensation ceiling for other CEOs. Though Musk's $56 billion compensation was rejected twice by courts, the chief of the EV maker launched an appeal in March to restore it. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Novo Nordisk A/S (NVO): Is This Incompetence? Wonders Jim Cramer
Novo Nordisk A/S (NVO): Is This Incompetence? Wonders Jim Cramer

Yahoo

time25 minutes ago

  • Yahoo

Novo Nordisk A/S (NVO): Is This Incompetence? Wonders Jim Cramer

We recently published . ABC is one of the stocks Jim Cramer recently discussed. Novo Nordisk A/S (NYSE:NVO), the Danish healthcare company, hasn't performed well in 2025. The shares have lost a whopping 43% year-to-date and sank by 22% in July after the firm cut its full-year growth guidance to 8% to 14% from an earlier 13% to 21%. Crucially, Novo Nordisk A/S (NYSE:NVO)'s downbeat guidance was on the back of worries about its weight loss drug Wegovy. Investors weren't pleased that the firm expects to struggle in the hot weight loss drug market. As for Cramer, he believes incompetence might have a role to play in Novo Nordisk A/S (NYSE:NVO)'s woes: 'Now that is, I felt, that borders on incompetence, given the fact that we know all of the different uses that are coming. But this company has been challenged, they seem way out of their league.' Copyright: dolgachov / 123RF Stock Photo Previously, the CNBC TV host discussed Novo Nordisk A/S (NYSE:NVO)'s exposure to sectoral tariffs by President Trump: '[If market should start thinking about sectoral tariffs after Trump's latest remarks] I mean when I heard it first I said okay, so they put a tariff on Novo Nordisk. It's really good for Eli Lilly. Now that's not necessarily what we're talking about but remember this price differential right now. . CVS, Eli Lilly versus Novo. So for Wegovy versus Zepbound. Be interesting to see what happens, I think it's very bullish for Eli Lilly.' While we acknowledge the potential of NVO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

U.S. Bancorp (USB): A Strong Buy Bank Stock with a Steady Dividend Track Record
U.S. Bancorp (USB): A Strong Buy Bank Stock with a Steady Dividend Track Record

Yahoo

time25 minutes ago

  • Yahoo

U.S. Bancorp (USB): A Strong Buy Bank Stock with a Steady Dividend Track Record

U.S. Bancorp (NYSE:USB) is included among the Best Strong Buy Dividend Stocks to Invest in Now. A high-powered banker making a deal in their modern office in the city. The company revealed on July 1 its plan to increase its quarterly dividend by 4%, raising the payout from $0.50 to $0.52 per share. This move came on the heels of the bank's solid performance in the Federal Reserve's stress test. In addition to the dividend increase, the company intends to proceed with share repurchases under its existing $5 billion buyback program. During the second quarter of 2025, U.S. Bancorp (NYSE:USB) reported diluted earnings per share of $1.11 and achieved a return on tangible common equity of 18%, along with a return on average assets of 1.08%. Notably, a year-over-year increase in top-line revenue, combined with disciplined expense management, contributed to 250 basis points of positive operating leverage (as adjusted) and led to an efficiency ratio of 59.2% for the quarter. Currently, U.S. Bancorp (NYSE:USB) offers a quarterly dividend of $0.50 per share and has a dividend yield of 4.34%, as of July 29. The company has been rewarding shareholders with growing dividends for the past 14 consecutive years. While we acknowledge the potential of USB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store